Hypoxic Ischemic Encephalopathy Clinical Trial
Official title:
Acute Kidney Injury in Asphyxiated Infants Treated by Therapeutic Hypothermia
This study aims to determine the effect of therapeutic hypothermia on reducing AKI in term and late-preterm infants with hypoxic ischemic encephalopathy as estimated by measurment of serum(s) neutrophil gelatinase-associated lipocalin(NGAL) and serum (s) cystatin-C.
The study will be conducted at the NICU of Mansoura University children's Hospital and
regional General Hospital where brain cooling is not available.
Infants will be identified in the delivery room or the NICU based on a per-specified
inclusion and exclusion criteria. The admitting physician will inform the study team upon
admitting the infants to prepare for obtaining consent form.
When a patient is admitted and satisfies the inclusion criteria, one of the investigators or
delegate will approach the parent(s). Patient identification will be done by admitting
residents or the nurse practitioners. Parents will be approached by the residents or the
nurse practitioners while the signature of the consent form in case of agreement will be
obtained by one of the investigators who are not responsible about the care of the infant.
Using language understandable to the parent(s), the study protocol will be described in
detail outlining the procedure and describing any potential risks. All parents will be
specifically informed that a decision not to participate in the research study will in no way
compromise their child's care. If the parent(s) agree that their child participate in the
study, written informed consent will be obtained. A copy of the consent form will be kept
with the investigators.
Infants will be classified into two groups, either group 1 (Cooled group) or group 2
(Non-cooled group) who missed opportunity to be identified within proper time.Categorization
will be center-based according to the feasibility of cooling devices at proper time (the
first 12 hours of the baby's life).
Group 1 (Cooled group) Cooling procedure We will fit a cooling cap (Olympic Medical Cool Care
System, Olympic Medical) around the head for 72 h. The system consists of a small
thermostatically controlled cooling unit with a pump that circulated water through the cap.
The initial water temperature is set between 8°C and 12°C. All infants will be nursed under a
radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature
and adjusted to maintain the rectal temperature at 33.5-34.5ºC. Adjustments will be made to
the cooling cap water temperature to stay within these limits. At the start of hypothermia,
the overhead heater will be turned off for 20-30 min to accelerate cooling, and then turned
back on once the rectal temperature had fallen to 35.5ºC.
Rewarming procedure At the end of the 72 h cooling period, the infants will slowly rewarmed
at no more than 0.5ºC /h until their temperature was within normal temperature range
(36.5-37.5ºC). The overhead heater can be adjusted as needed, to rewarm the infant. The
infant's temperature will be be carefully monitored for at least 4 hours to prevent rebound
hyperthermia, as this might be detrimental.
Group 2 (Non-cooled group):
Infants in the non-cooled group received the standard of care and will placed under radiant
heaters or in incubators, which will be servo-controlled according to the abdominal skin
temperature to maintain the rectal temperature at 37.0± 0.2°C.
Laboratory test results Serum creatinine, electrolyte levels, and liver function tests will
be assessed before the start of cooling (baseline); at 72 during cooling; and then on days
and 10 of life as clinically indicated. Blood sample for sNGAL and cystatine C will be
obtained at Day 1, 4 and 10 of life.
Statistical Analysis Statistical analysis will be performed using SPSS statistical software
(version 16; SPSS, Chicago, Illinois). Student-t test or Mann-Whitney test will be used to
compare continuous variables and Chi-square test or Fisher's exact test will be used for
categorical variables. The diagnostic accuracy of the sNGAL and cystatine C tested in this
study for identifying AKI will be evaluated by constructing receiver operating
characteristics (ROC) curves. A p-value of <0.05 is considered to be statistically
significant. All data will be expressed as mean ± standard deviation unless otherwise stated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT01962233 -
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy
|
Phase 1 | |
Completed |
NCT01683383 -
California Transport Cooling Trial
|
N/A | |
Completed |
NCT01471015 -
Darbe Administration in Newborns Undergoing Cooling for Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01649648 -
Autologous Cord Blood Cells for Brain Injury in Term Newborns
|
Phase 1 | |
Completed |
NCT01481207 -
Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy
|
||
Withdrawn |
NCT00993564 -
Magnetic Resonance Imaging (MRI) Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy (HIE)
|
N/A | |
Completed |
NCT00945789 -
Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)
|
Phase 1/Phase 2 | |
Completed |
NCT00097097 -
Neonatal Resuscitation in Zambia
|
Phase 3 | |
Recruiting |
NCT02621944 -
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
|
Early Phase 1 | |
Not yet recruiting |
NCT02605018 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01128673 -
MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE)
|
N/A | |
Completed |
NCT01732146 -
Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy
|
Phase 3 | |
Completed |
NCT02349672 -
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
|
||
Completed |
NCT02826941 -
Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy
|
Phase 2 | |
Active, not recruiting |
NCT01138176 -
Whole Body Cooling Using Phase Changing Material
|
Phase 1/Phase 2 | |
Recruiting |
NCT02578823 -
Targeted Temperature Management After In-Hospital Cardiac Arrest
|
N/A | |
Terminated |
NCT01765218 -
Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01241019 -
Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia
|
Phase 2 | |
Completed |
NCT00620711 -
Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy
|
Phase 1 |